A Mass Balance Study of [14C] MT1013 in Hemodialysis Subjects With Secondary Hyperparathyroidism

Recruiting Phase 1 Interventional Study
Hemodialysis Subjects With Secondary Hyperparathyroidism
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 1
Study type
Interventional
Purpose
Treatment
Participants needed
6 (estimated)
Sponsor
Shaanxi Micot Pharmaceutical Technology Co., Ltd. · Industry
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

MT1013 is a first-in-class dual-target agonist.This study is being conducted to determine the mass balance and routes of excretion of total radioactivity after the dose of \[14C\] MT1013.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * 1\. Male or postmenopausal female participants, aged 18 years or older, with a confirmed diagnosis of SHPT. * 2\. The BMI is between 18 kg/m2 and 35 kg/m2; * 3\. The subjects must undergo regular maintenance hemodialysis three times a week for at least three months; * 4\. With…
Contacts

Wei Zhao, Ph.D.

0531-89268960

zhao4wei2@hotmail.com

CONTACT

Yong Wei, Ph.D.

0531-89269002

Weiyong0901@163.com

CONTACT